Musculoskeletal soft tissue disorders and injuries are a burden that needs a therapy. In recent times, many therapies are emerging and all these are undergoing trials on animal models. Most of these therapies focus on the several growth factors that can alleviate healing. The result of administering and manipulating these factors are the subject of research. But there are limitations regarding restricted application procedures, reliance on carriers and instability.
All recent studies have shown BPC 157 to be therapeutic for functional restoration and healing of soft tissue injuries. Rodent models are the common factors in most of these researches and the effectiveness of this peptide on human beings is not yet confirmed. But BPC 157 shows strong potential to treat hypocellular and hypovascular soft tissues including ligaments and tendons. Research works have proven that this peptide is also beneficial for systematic problems including hypermagnesia and hypercalamia. More research is needed to properly understand the healing mechanism. Researchers who are holding a license can Buy BPC-157 USA for laboratory use.
Musculoskeletal injuries in daily life
This kind of injury can take place during everyday activity and sports as well. The injuries that happen particularly during sports activities are often the results of injury to the fibers due to complete or incomplete tearing. Several factors decide the healing time and capacity of recovery of these tissues. Even the vascular nature and cellular composition of the tissue matter when it comes to recovery. The recovery phase can be divided into three phases: inflammatory phase, repairing phase and remodeling phase. The injured tissues lack the ultra-structural and biochemical characteristics that they had before the injury. BPC-157 or Bepecin is an amino-acid fragment which is termed as ‘synthetic’. It is called synthetic because of being derived from another protein though contains all natural compounds.
The spontaneous healing of ligament and tendon is poor because of limited blood supply. Research showed improved recovery measures with systematic delivery of BPC 157. Microscopic analysis of rats’ transected Achilles tendon showed less granulocyte, greater mononuclear count, increased fibroblasts along with superior formation after recovering with BPC 157. This peptide was capable of re-establishing full tendon integrity while the treated defects had smaller size and depth. This peptide was delivered topically as a cream, through drinking water and via administration of intraperitoneal administration. This research result suggests that this peptide can be successfully administered through various delivery mechanisms.
Research conducted on transected and detached Achilles tendon in rodent models proved its capability to promote tendon-to-bone healing. The peptide proved to be beneficial even in the presence of corticosteroids which have long been remained as one of the prevalent though controversial treatment for soft tissue damage. The capability of BPC 157 to counteract corticosteroid proves its potential to be applied alongside prevalent and conventional treatment methods. Research has also suggested that BPC 157 might be able to help in recovering of systematic muscular injuries caused by direct trauma. This peptide needs even more research for understanding the mechanism of healing and its effects on human system.